Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7621816 | 1.00 | KISS1R (0.34) | KISS1RKDM1A | |
| SCHEMBL22171773 | 0.96 | — | — | |
| SCHEMBL8018919 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL8751696 | 0.92 | KDM1A (0.35) | KISS1RKDM1A | |
| Hydrochloric Acid SCHEMBL8751699 | 0.92 | KDM1A (0.35) | KISS1RKDM1A | |
| SCHEMBL12377079 | 0.82 | — | — | |
| SCHEMBL15592018 | 0.82 | — | — | |
| SCHEMBL22788418 | 0.80 | KISS1R (0.33) | KISS1R | |
| SCHEMBL24372442 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL22771746 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6576791-B1 | Local anesthetic compounds and uses | THERAVANCE, INC. | 2003-06-10 | — | — | US | disclosed |
| US-20030044845-A1 | Novel therapeutic agents for membrane transporters | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-03-06 | — | — | US | disclosed |
| US-6495681-B1 | PRODUCING LOCAL ANESTHESIA OF LONG-DURATION. THE COMPOUNDS OF THIS INVENTION ARE MULTIBINDING COMPOUNDS THAT COMPRISE FROM 2 TO 10 LIGANDS COVALENTLY ATTACHED TO A LINKER OR LINKERS, EACH LIGAND BEING CAPABLE OF BINDING TO A LIGAND BINDING SITE | THERAVANCE INC. | 2002-12-17 | — | — | US | disclosed |
| US-6462034-B1 | MULTIBINDING COMPOUNDS CONTAINING A SYMETRICAL DIAMINOTETRA-ETHERDODECANE RING WITH TWO SECONDARY AMIDE AND ADDITIONAL SUBSTITUENTS; VOLTAGE GATED SODIUM CHANNEL MODULATORS; LONG DURATION | THERAVANCE, INC. | 2002-10-08 | — | — | US | disclosed |
| US-6436919-B1 | LOCAL ANESTHETICS THAT HAVE LONGER DURATION OF ACTION WHILE REDUCING UNDESIRED SIDE EFFECTS | THERAVANCE INC. | 2002-08-20 | — | — | US | disclosed |
| US-6337423-B1 | BIND TO VOLTAGE-GATED SODIUM ION CHANNELS TO MODULATE ACTIVITY | ADVANCED MEDICINE, INC. | 2002-01-08 | — | — | US | disclosed |
| WO-1999064045-A9 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | ADVANCED MEDICINE INC (US) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030044845-A1 | Novel therapeutic agents for membrane transporters | SLC47A2, SLC8B1, SLC47A1 | KISS1R 3305/4885KDM1A 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.